Truist reiterates Buy on Boston Scientific stock amid 2027 outlook

Truist reiterated a Buy rating and $51 target on Boston Scientific (BSX) despite 2027 growth challenges from a cyberattack. The firm expects negative growth in 2027 but sees a recovery in 2028. BSX's Q3 2026 results missed EPS estimates but beat revenue forecasts. Multiple analysts adjusted price targets and ratings due to the outlook.

Original reporting
Published Oct 29, 2026, 5:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 5:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BSX
Bearish
high confidence
Mentioned
$BSX
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BSXBearishMed
01

Why it matters

Analyst consensus now reflects weaker growth outlook, with price targets ranging from $48 to $52 and a shift to Perform from Outperform.

02

Market read

Analyst rating and target revisions provide fresh guidance that could move BSX lower in the short term.

03

What to watch

Potential upside from delayed product launches in 2028 and a 5% portfolio growth projection.

Relevance 7/10Novelty 6/10Timing: today

Background

Boston Scientific reported mixed Q3 2026 results, missing EPS expectations and attributing the shortfall to a cyber‑attack that disrupted manufacturing and shipping.

Company-level read

Ticker impact

$BSXBearishHigh confidence
Context

Truist reiterated a Buy rating with a $51 price target and highlighted a cyber‑attack‑driven negative outlook for 2027, while multiple analysts cut price targets and downgraded the stock.

Expected impact

likely pressure as the market prices in weaker 2027 guidance and lower targets

Evidence & confidence

Multiple sell‑side firms (Oppenheimer, RBC, Mizuho, Canaccord) reduced targets and ratings, indicating consensus on reduced growth expectations.

Market effects

Medical device sector may face broader scrutiny on cyber‑risk and growth forecasts.

U.S. healthcare stocks could see modest pullback amid heightened risk perception.

Limited; impact confined to Boston Scientific and peers.

Counterpoint

If the cyber‑attack impact is overstated, the stock could rebound on its strong cash flow and pipeline.

Key entities

  • Truist Securities

    Reiterated Buy rating and $51 price target.

  • Oppenheimer

    Downgraded to Perform.

  • RBC Capital

    Reduced target to $52.

  • Mizuho

    Cut target to $50.

  • Canaccord

    Reduced target to $48.

Related articles

$BSXMed

BSX's Weak Solvency and Cash Conversion Raise Financing Risk

Boston Scientific (BSX) reported $609M in cash, $11.95B in debt, and Q3 free cash flow of $867M. Adjusted gross margin fell 300bps YoY to 68% due to a cybersecurity incident. BSX lowered its full-year free cash flow outlook to $3.6B. The company faces margin pressure, pricing pressure in China, and acquisition-related obligations. BSX shares have declined 56% YoY, trading at a 12-month forward P/S of 3.00X. Analysts have reduced BSX's 2026 earnings estimate by 2.2% over the past 30 days.

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.